|
|
|
Therion Biologics Management Team
Therion is led by a group of seasoned management professionals, with extensive experience in research and development, product commercialization and financial strategy. Together, the team supports the advancement of Therion's clinical programs and the growth of its core business. Members of Therion's Management Team include the following:
Mark W. Leuchtenberger
President, Chief Executive
Officer
Dennis L. Panicali,
Ph.D.
Chief Scientific
Officer
George A. Eldridge
Senior Vice President, Chief Financial Officer
Thomas J. Schuetz, M.D., Ph.D.
Chief Medical Officer
Richard H. Woodrich
Senior Vice President, Business
Development
Michael S. Wyand, D.V.M., Ph.D.
Senior Vice President, Research and Development
Mary Lou Horzempa,
RAC
Vice President, Regulatory
Affairs
Erin E. Lanciani
Vice President, Human Resources
Gail P. Mazzara,
Ph.D.
Vice President, Research &
Development
Suman T. Patel,
Ph.D.
Vice President, Quality
|
|
|
|
Mark W. Leuchtenberger
President, Chief Executive Officer
Mark Leuchtenberger joined Therion as President and CEO from Biogen, where he served as Vice President, International. In this capacity, he led all commercial operations outside of North America. Mark joined Biogen in 1990 as Product Manager and served as Program Executive for Amevive�, until assuming Avonex® program leadership in 1993. In this role, Mark was responsible for managing the late-stage development, registration, marketing and North American launch of Avonex®. During his tenure at Biogen, he held several senior positions, including Vice President of Sales, Marketing and Business Development where he oversaw the company's global market, licensing and strategic partnership activities. Prior to Biogen, he worked as a Senior Consultant at Bain and Company and specialized in healthcare products and services. Mark received a M.B.A. from the Yale School of Management and a B.A. from Wake Forest University.
Back
to the
top
Dennis L. Panicali, Ph.D.
Chief Scientific Officer
Dennis Panicali, who is the Company's first Chief Scientific Officer, founded Therion Biologics in 1991 and served as President and CEO for 12 years. He is a member of Therion's Board of Directors, and directs the scientific advancement and expansion of Therion's product pipeline. From 1986 to 1991, Dennis was Vice President of Product Development at Applied bioTechnology, Inc. (AbT). Dennis pioneered the development of pox virus vectors for use in immune therapies and cancer research at the New York State Department of Health Centers for Laboratories and Research. Dennis holds a B.S. in Microbiology from the University of Connecticut and a Ph.D. in Cell and Molecular Biology from the Medical College of Georgia.
Back
to the
top
George A. Eldridge
Senior Vice President, Chief Financial Officer
George Eldridge, previously Vice President of Finance and Chief Financial Officer of Curis, joined Therion as Chief Financial Officer. While with Curis and, prior to merging, Ontogeny, Inc., George was responsible for securing corporate investments and or raising over $100 million in three institutional equity offerings. He also led the successul integration of all departments in the three-way merger between Creative BioMolecules, Ontogeny and Reprogenesis that created Curis in August of 2000. Prior to joining Curis, George was Chief Financial Officer for Boston Life Sciences, Inc., and was an investment banker at Kidder Peabody & Co., Inc. George earned a M.B.A. from the University of Chicago, and a B.A. in government and economics from Dartmouth College.
Back
to the
top
Thomas J. Schuetz, M.D., Ph.D.
Chief Medical Officer
Tom Schuetz joined Therion as Chief Medical Officer in 2003. Previously, at Transkaryotic Therapies (TKT), he served as Vice President of Clinical Affairs where he supervised all aspects of clinical development from Phase I through IV. He developed the clinical research program which led to European Union approval of Replagal™, an enzyme replacement therapy for Fabry Disease. He also supervised the Hemophilia A Gene Therapy clinical development program. Prior to TKT, he served as Chief Medical Resident at Massachusetts General Hospital, and he was an Oncology fellow at the Dana Farber Cancer Institute in Boston. Tom is Board Certified in Internal Medicine and Medical Oncology. He received his M.D. from Harvard Medical School, Ph.D. from Harvard University, and B.S. in Chemistry from Xavier University.
Back
to the
top
Richard H. Woodrich
Senior Vice President, Business Development
Dick Woodrich joined Therion as Senior Vice President of Business Development in August 1999. Dick has more than 16 years of corporate development experience in biotechnology companies, formerly serving as Executive Vice President and Chief Operating Officer at CytoMed, Inc. Prior to CytoMed, he served as President, Chief Operating Officer and Director of Oculon Corporation and as Chief Financial Officer of AbT. Dick holds a B.S. in Management from Rensselaer Polytechnic Institute and received his M.B.A. from Harvard Business School.
Back
to the
top
Michael S. Wyand, D.V.M., Ph.D.
Senior Vice President, Research and Development
Michael Wyand brings 12 years of experience in biopharmaceutical discovery and development to Therion. Prior to joining Therion, Michael was President and Chief Scientific Officer of the Mason Division of Primedica Corporation, and President of Commonwealth LifeSciences, Inc. Throughout his career, he has gained extensive experience in the area of technology assessment, therapeutic drug development, and IND program design of biologics and small molecules including DNA based vaccines. Michael received his D.V.M. from Purdue University and his Ph.D. from the University of Connecticut.
Back
to the
top
Mary Lou Horzempa, RAC
Vice President, Regulatory Affairs
Mary Lou Horzempa has served as Therion's Vice President of Regulatory Affairs since 1997. Prior to this position, she held other regulatory affairs positions at Therion and AbT. Before joining AbT, Mary Lou was Assistant Director of Quality Assurance and Manager of Product Compliance at Analytab Products. Mary Lou holds a B.S. in Microbiology from the University of Massachusetts and a M.S. in Medical Microbiology from the University of Washington.
Back
to the
top
Erin E. Lanciani
Vice President, Human Resources
Erin Lanciani joined Therion as Vice President, Human Resources. Erin served as the Director of Human Resources for ViaCell, prior to joining Therion, where she developed a strategic growth plan and formulated progressive recruitment strategies and reward systems as ViaCell�s work force grew by more than 300 percent. Erin also established a company-wide communications strategy and performance management initiative, which established the foundation of a high-performing corporate culture. Before joining ViaCell, she was a Human Resources Business Partner at Genzyme Corporation for the Therapeutics and International Divisions and was a Founder/Partner of Outsourcing Solutions, Inc., a human resources consulting firm. Erin received a B.S. in Business Administration from Northeastern University.
Back
to the
top
Gail P. Mazzara, Ph.D.
Vice President, Research &
Development
Gail Mazzara joined Therion in 1991 and has held several positions at the Company, including Senior Director of Research & Development. In her last position, at AbT, she served as Manager of Vaccine Development. Gail holds an A.B. in biology from Harvard University and a M.S. and Ph.D. in Bacteriology from the University of Wisconsin, Madison.
Back
to the
top
Suman T. Patel, Ph.D.
Vice President, Quality
Suman Patel joined Therion in 2002 from Millennium Pharmaceuticals where he served as Senior Director, Quality Assurance and Quality Control, and was responsible for devising assurance and quality strategies and business plans. He also provided chemistry manufacturing and controls (CMC) support around product marketing and completed a major quality assurance/control organization development for the company. With over 17 years of biopharmaceutical and pharmaceutical experience, Suman also held senior management positions at Biogen, Inc., Schering-Plough Research Institute, and Eastman Kodak Company. Suman received a B.S. in Zoology, a M.S. in Physiological Chemistry and Reroductive Physiology, and a Ph.D. from the University of Baroda, India.
Back
to the
top
Copyright © Therion
Biologics Corporation.
|
